Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | MTOR | P42345 | 2/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.61 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.61 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | BLM | P54132 | 2/20 | 0.58 |
| ▸ | GMNN | O75496 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | HBB | P68871 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zebularine SCHEMBL12595413 | 1.00 | CDA (1.00) | CDAMAPTLMNAMTORTHRB | |
| Zebularine SCHEMBL13032 | 1.00 | CDA (1.00) | CDAMAPTLMNAMTORTHRB | |
| Zebularine SCHEMBL7122633 | 1.00 | CDA (1.00) | CDAMAPTLMNAMTORTHRB | |
| Zebularine SCHEMBL11910465 | 1.00 | CDA (1.00) | CDAMAPTLMNAMTORTHRB | |
| Zebularine SCHEMBL2563757 | 1.00 | CDA (1.00) | CDAMAPTLMNAMTORTHRB | |
| Zebularine SCHEMBL1649826 | 1.00 | CDA (1.00) | CDAMAPTLMNAMTORTHRB | |
| Zebularine SCHEMBL19656926 | 1.00 | CDA (1.00) | CDAMAPTLMNAMTORTHRB | |
| Zebularine SCHEMBL21842491 | 1.00 | CDA (1.00) | CDAMAPTLMNAMTORTHRB | |
| Zebularine SCHEMBL21474114 | 1.00 | CDA (1.00) | CDAMAPTLMNAMTORTHRB | |
| Zebularine SCHEMBL1444853 | 1.00 | CDA (1.00) | CDAMAPTLMNAMTORTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255996-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-20230241086-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2023-08-03 | — | — | US | disclosed |
| US-11571436-B2 | Oral formulations of cytidine analogs and methods of use thereof | CELGENE CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210196723-A1 | Modulators of DUX4 for Regulation of Muscle Function | SONIC MASTER LTD (VG) | 2021-07-01 | — | — | US | disclosed |
| US-20210100805-A1 | COMBINATION THERAPY FOR TREATING MALIGNANCIES | SERVIER PHARMACEUTICALS LLC | 2021-04-08 | — | — | US | disclosed |
| US-20200405737-A1 | COMBINATION THERAPY FOR TREATING MALIGNANCIES | SERVIER PHARMACEUTICALS LLC | 2020-12-31 | — | — | US | disclosed |
| US-20200208116-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-10695352-B2 | Combination therapy for treating malignancies | CELGENE CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200155610-A1 | MESENCHYMAL STEM CELLS WITH ENHANCED IMMUNOSUPPRESSIVE CAPABILITY | JUVENESCENCE LIMITED (GB) | 2020-05-21 | — | — | US | disclosed |
| US-10653710-B2 | Combination therapy for treating malignancies | AGIOS PHARMACEUTICALS, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-10226478-B2 | Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia | CYCLACEL LIMITED (GB) | 2019-03-12 | — | — | US | disclosed |
| US-10220050-B2 | Isotopologues of 5-azacytidine | CELGENE CORPORATION (US) | 2019-03-05 | — | — | US | disclosed |
| US-10028973-B2 | Using DNA methyltransferase inhibitors to treat calcific aorta valve disease | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180153916-A1 | ISOTOPOLOGUES OF 5-AZACYTIDINE | CELGENE CORPORATION | 2018-06-07 | — | — | US | disclosed |
| US-9693987-B2 | Methods for treating cancers using oral formulations of cytidine analogs | CELGENE CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170065639-A1 | MESENCHYMAL STEM CELLS WITH ENHANCED IMMUNOSUPPRESSIVE CAPABILITY | ESCAPE THERAPEUTICS, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20110319355-A1 | METHODS FOR TREATING NON-SMALL CELL LUNG CANCER USING 5-AZACYTIDINE | PHARMION LLC | 2011-12-29 | — | — | US | disclosed |
| US-20110301199-A1 | COMPOSITIONS AND METHODS FOR TREATING MYELODYSPLASTIC SYNDROME | TELIK, INC. | 2011-12-08 | — | — | US | disclosed |
| US-20110207692-A1 | COMBINATIONS OF SAPACITABINE OR CNDAC WITH DNA METHYLTRANSFERASE INHIBITORS SUCH AS DECITABINE AND PROCAINE | CYCLACEL LIMITED (GB) | 2011-08-25 | — | — | US | disclosed |
| US-20090286752-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301199-A1 | COMPOSITIONS AND METHODS FOR TREATING MYELODYSPLASTIC SYNDROME | EZH2, TET2, DNMT3A | CDA 602/4885MAPT 2774/4885LMNA 1189/4885 |
| US-20210196723-A1 | Modulators of DUX4 for Regulation of Muscle Function | DDX21, MBNL1, MECP2 | CDA 813/4885MAPT 3643/4885LMNA 1943/4885 |
| US-10028973-B2 | Using DNA methyltransferase inhibitors to treat calcific aorta valve disease | DNMT1, DNMT3A, DNMT3B | CDA 247/4885MAPT 2506/4885LMNA 1885/4885 |
| US-10653710-B2 | Combination therapy for treating malignancies | IDH3B, IDH1, IDH3A | CDA 225/4885MAPT 4666/4885LMNA 3532/4885 |
| US-20230241086-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | DCTD, CDA, NT5C2 | CDA 2/4885MAPT 4320/4885LMNA 1285/4885 |
| US-20110207692-A1 | COMBINATIONS OF SAPACITABINE OR CNDAC WITH DNA METHYLTRANSFERASE INHIBITORS SUCH AS DECITABINE AND PROCAINE | DNMT1, DCTD, DNMT3A | CDA 13/4885MAPT 2897/4885LMNA 578/4885 |
| US-20170065639-A1 | MESENCHYMAL STEM CELLS WITH ENHANCED IMMUNOSUPPRESSIVE CAPABILITY | HLA-C, HLA-B, HLA-DRB1 | CDA 152/4885MAPT 4052/4885LMNA 3899/4885 |
| US-20090286752-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | DCTD, CDA, NT5C2 | CDA 2/4885MAPT 4320/4885LMNA 1285/4885 |
| US-10695352-B2 | Combination therapy for treating malignancies | IDH3B, IDH2, IDH3A | CDA 163/4885MAPT 4288/4885LMNA 2767/4885 |
| US-20180153916-A1 | ISOTOPOLOGUES OF 5-AZACYTIDINE | UNG, DCTD, DPYD | CDA 14/4885MAPT 4224/4885LMNA 2638/4885 |
| US-20200155610-A1 | MESENCHYMAL STEM CELLS WITH ENHANCED IMMUNOSUPPRESSIVE CAPABILITY | HLA-C, HLA-B, HLA-DRB1 | CDA 152/4885MAPT 4052/4885LMNA 3899/4885 |
| US-20230255996-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | DCTD, CDA, NT5C2 | CDA 2/4885MAPT 4320/4885LMNA 1285/4885 |
| US-11571436-B2 | Oral formulations of cytidine analogs and methods of use thereof | DCTD, CDA, NT5C2 | CDA 2/4885MAPT 4320/4885LMNA 1285/4885 |
| US-10220050-B2 | Isotopologues of 5-azacytidine | DNMT1, TOP2A, TET2 | CDA 86/4885MAPT 3326/4885LMNA 3478/4885 |
| US-20110319355-A1 | METHODS FOR TREATING NON-SMALL CELL LUNG CANCER USING 5-AZACYTIDINE | DCTD, NSUN2, RNMT | CDA 8/4885MAPT 4828/4885LMNA 2657/4885 |
| US-20200208116-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | SLC2A3, SLC2A2, SLC2A1 | CDA 1575/4885MAPT 4010/4885LMNA 3563/4885 |
| US-20210100805-A1 | COMBINATION THERAPY FOR TREATING MALIGNANCIES | IDH3B, IDH2, IDH3A | CDA 163/4885MAPT 4288/4885LMNA 2767/4885 |
| US-10226478-B2 | Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia | DNMT3A, DNMT1, MCL1 | CDA 28/4885MAPT 4386/4885LMNA 2753/4885 |
| US-20200405737-A1 | COMBINATION THERAPY FOR TREATING MALIGNANCIES | IDH3B, IDH3A, IDH1 | CDA 223/4885MAPT 4333/4885LMNA 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.